Navlimetostat Clinical Trials (2026): 2 Studies for Healthy Participants & Non-Small Cell Lung Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 Navlimetostat clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Healthy Participants & Non-Small Cell Lung Cancer) and 81 total planned enrollment. 2 Navlimetostat clinical trials are actively recruiting at 2 U.S. sites across 2 states. Most recent activity: NCT07579221 (Aug 2031).
Where to Participate: All Navlimetostat Trial Sites in the U.S. (2 sites across 2 states)
Every actively recruiting Navlimetostattrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| GA | CenExel iResearch - Decatur | Decatur30030 | NCT07544628 | Map |
| TX | PPD | Austin78744 | NCT07544628 | Map |
Navlimetostat clinical trials at a glance: phase × recruitment status
| Phase | recruiting | not yet recruiting | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P1/P2 | 1 | 1 |
Recruiting Navlimetostat clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07579221 | Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer | P1/P2 | Non-Small Cell Lung Cancer | 17 | Nov 2026 |
| NCT07544628 | A Phase 1 Study of Navlimetostat Tablet Formulations | P1 | Healthy Participants | 64 | Apr 2026 |
Navlimetostat clinical trials by indication
Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07579221 | — | P1/P2 | not yet recruiting | Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer |
Healthy Participants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07544628 | — | P1 | recruiting | A Phase 1 Study of Navlimetostat Tablet Formulations |
All Navlimetostat trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07579221 | Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer | P1/P2 | not yet recruiting | 17 | M.D. Anderson Cancer Center | Nov 2026 | |
| NCT07544628 | A Phase 1 Study of Navlimetostat Tablet Formulations | P1 | recruiting | 64 | Bristol-Myers Squibb | Apr 2026 |
Navlimetostat clinical trials: frequently asked questions
- How many Navlimetostat clinical trials are there?
- 2 Navlimetostat clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are Navlimetostat clinical trials recruiting in 2026?
- Yes — 1 Navlimetostat trial is actively recruiting in 2026, with 2 U.S. sites across 2 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Navlimetostat being studied for?
- Navlimetostat is being studied for Healthy Participants, Non-Small Cell Lung Cancer. The trials are grouped by indication on this page.
- What phase is Navlimetostat in?
- Navlimetostat clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Navlimetostat clinical trials?
- The lead sponsor across the most Navlimetostat trials is Bristol-Myers Squibb, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Navlimetostatas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: